Zühlke vs Phillips-Medisize: full comparison for 2026
Quick verdict
Zühlke (4.4/5) edges ahead of Phillips-Medisize (3.9/5) overall. Zühlke is the better choice for european medtech firms modernizing device software. Phillips-Medisize is the stronger option for drug delivery devices needing high-volume production. The right choice depends on your project size, budget, and required tech stack.
Zühlke vs Phillips-Medisize: head-to-head summary
| Criterion | Zühlke | Phillips-Medisize |
|---|---|---|
| Founded | 1968 | 1964 |
| HQ | Schlieren, Switzerland | Hudson, WI, USA |
| Team size | 1,500–2,000 | ~7,000 |
| Rating | 4.4 / 5 | 3.9 / 5 |
| Primary differentiator | A device engineering practice and a large digital practice under one owner, useful when a device program is really a platform program | Design, molding and assembly of drug delivery devices under one global quality system |
| Pricing model | Time and materials, fixed project | Development contract plus manufacturing supply agreement |
| Min. engagement | Not disclosed | Not disclosed |
| Primary tech stack | Embedded C/C++, Embedded Linux, Cloud (AWS/Azure) | Injection molding, Automated assembly, BLE |
| Industries served | Digital health, Diagnostics & lab devices, Surgical & therapeutic devices, Financial services | Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices |
Zühlke vs Phillips-Medisize: overview
Zühlke
Partner-owned since its 1968 founding in Switzerland, Zühlke is headquartered in Schlieren near Zurich, with teams in Germany, Austria, the UK, Serbia and Asia. Its headcount is somewhere between 1,500 and 2,000 depending on the source. In healthcare it covers regulated device and systems engineering, connected-device software and the cloud and analytics platforms around devices, and it states more than 50 years of medtech experience (per company website; independently unverifiable).
Phillips-Medisize
Phillips-Medisize is a subsidiary of Molex, itself owned by Koch Industries, and provides outsourced design, development and manufacturing to pharma, diagnostics and medical device companies. It is based in Wisconsin and has about 7,000 employees. Molex's purchase of inhalation specialist Vectura added combination-product expertise, and the combined team includes more than 1,200 engineers and scientists across 30 sites. A $110M manufacturing campus in Katowice, Poland, opened in November 2023.
Services and capabilities: Zühlke vs Phillips-Medisize
| Capability | Zühlke | Phillips-Medisize |
|---|---|---|
| Electronics & PCB design | ✓ | ✓ |
| Firmware & embedded software | ✓ | ✗ |
| SaMD & companion apps | ✓ | ✗ |
| Connected devices & IoT | ✓ | ✗ |
| Industrial design & human factors | ✗ | ✗ |
| Mechanical engineering | ✗ | ✓ |
| Device cybersecurity | ✗ | ✗ |
| Regulatory & QMS support | ✓ | ✓ |
| Manufacturing & scale-up | ✗ | ✓ |
Tech stack comparison: Zühlke vs Phillips-Medisize
| Framework / platform | Zühlke | Phillips-Medisize |
|---|---|---|
| Embedded C/C++ | ✓ | N/A |
| Embedded Linux | ✓ | N/A |
| RTOS | N/A | N/A |
| BLE | N/A | ✓ |
| Cloud (AWS/Azure) | ✓ | N/A |
| IEC 62304 | ✓ | N/A |
| ISO 14971 | N/A | N/A |
| ISO 13485 QMS | N/A | ✓ |
| Qt | ✓ | N/A |
Pricing comparison: Zühlke vs Phillips-Medisize
| Criterion | Zühlke | Phillips-Medisize |
|---|---|---|
| Minimum engagement | Not disclosed | Not disclosed |
| Engagement models | Consulting, Dedicated team, Fixed project, Time & materials | Fixed project, Manufacturing contract |
| Rate transparency | Not public | Not public |
| Price tier | Mid-market | Mid-market |
Target audience comparison: Zühlke vs Phillips-Medisize
| Dimension | Zühlke | Phillips-Medisize |
|---|---|---|
| Best company size | Startup to mid-market | Startup to mid-market |
| Best industries | Digital health, Diagnostics & lab devices, Surgical & therapeutic devices | Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices |
| Best use cases | Rebuilding the embedded and cloud software of an established diagnostics platform, EU MDR remediation of legacy device software | Autoinjector or pen injector development and production, Inhaler device for a pharma combination product |
| Typical project type | Consulting | Fixed project |
Zühlke vs Phillips-Medisize: pros and cons
| Zühlke | |
|---|---|
| + | Partner ownership keeps the firm independent of a large holding group |
| + | Large enough to staff hardware, embedded, cloud and data roles at the same time |
| + | Delivery centres in Serbia and Asia give some cost flexibility compared with all-Swiss teams |
| + | Experience with EU MDR environments in German-speaking markets |
| - | Much of the firm works outside healthcare, so check that the proposed team is from the medtech practice |
| - | Swiss and German rates are high for the onshore part of a team |
| - | Industrial design and manufacturing are not core offerings |
| Phillips-Medisize | |
|---|---|
| + | Very large manufacturing footprint across the US, Europe and Asia |
| + | Vectura deal added deep inhalation and combination-product skills |
| + | Development and manufacturing under one quality system |
| + | Experience with connected drug delivery |
| - | Owned by Molex and Koch Industries, so it suits large pharma more than small startups |
| - | Development work is usually tied to a manufacturing agreement |
| - | Less suited to software-heavy or early research projects |
Who should choose Zühlke?
A typical fit: rebuilding the embedded and cloud software of an established diagnostics platform.
A device engineering practice and a large digital practice under one owner, useful when a device program is really a platform program. Minimum engagement is not publicly disclosed. Works best with clients in Digital health, Diagnostics & lab devices, Surgical & therapeutic devices, Financial services.
Who should choose Phillips-Medisize?
A typical fit: autoinjector or pen injector development and production.
Design, molding and assembly of drug delivery devices under one global quality system. Minimum engagement is not publicly disclosed. Works best with clients in Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices.
Decision matrix: Zühlke vs Phillips-Medisize
| Your situation | Recommended choice |
|---|---|
| You need full-ownership delivery on a defined project scope | Zühlke |
| You need a large dedicated team for an ongoing programme | Zühlke |
| Your budget is at the lower end | Compare: Zühlke (Not disclosed) vs Phillips-Medisize (Not disclosed) |
| You need specialist depth in a specific vertical | Zühlke |
| You need staff augmentation or team extension | Neither; consider alternatives that offer staff aug |
| You need consulting before committing to a build | Both may offer discovery engagements |
Use case fit: Zühlke vs Phillips-Medisize
| Use case | Zühlke fit | Phillips-Medisize fit | Winner |
|---|---|---|---|
| Rebuilding the embedded and cloud software of an established diagnostics platform | Strong | Limited | Zühlke |
| EU MDR remediation of legacy device software | Strong | Limited | Zühlke |
| Autoinjector or pen injector development and production | Limited | Strong | Phillips-Medisize |
| Inhaler device for a pharma combination product | Limited | Strong | Phillips-Medisize |
Verdict: Zühlke vs Phillips-Medisize
Zühlke (4.4/5) is the stronger overall choice for most Medical Device Development projects. A device engineering practice and a large digital practice under one owner, useful when a device program is really a platform program.
Phillips-Medisize (3.9/5) is worth a look if you need inhaler device for a pharma combination product. If your situation matches that, Phillips-Medisize is a competitive option.
Related comparisons
Zühlke vs Phillips-Medisize FAQ
Is Zühlke better than Phillips-Medisize?
Zühlke (4.4/5) scores higher overall, but "better" depends on your use case. Zühlke's strongest advantage: partner ownership keeps the firm independent of a large holding group. Phillips-Medisize's strongest advantage: very large manufacturing footprint across the US, Europe and Asia.
How do Zühlke and Phillips-Medisize differ in pricing?
Zühlke uses time and materials, fixed project pricing. Phillips-Medisize uses development contract plus manufacturing supply agreement pricing. Neither firm publishes a full rate card; a discovery call is required for project-specific quotes.
Which is better for enterprise: Zühlke or Phillips-Medisize?
Zühlke is the larger team and typically the better enterprise-scale choice. For very large programmes, verify team size and compliance coverage directly with each company before shortlisting.
What are the main differences between Zühlke and Phillips-Medisize?
Zühlke's primary differentiator is: a device engineering practice and a large digital practice under one owner, useful when a device program is really a platform program. Phillips-Medisize's primary differentiator is: Design, molding and assembly of drug delivery devices under one global quality system. They also differ in team size (1,500–2,000 vs ~7,000), minimum engagement (Not disclosed vs Not disclosed), and primary industries served (Digital health, Diagnostics & lab devices vs Drug delivery, Diagnostics & lab devices).
Verify all details directly with each company before making a decision.